Abstract
The kappa opioid receptor (KOR) and its primary cognate ligands, the dynorphin peptides, are involved in diverse physiological processes. Disruptions to the KOR/dynorphin system have been found to likely play a role in multiple neuropsychological disorders, and hence KOR has emerged as a potential therapeutic target. Targeting KOR is complicated by close homology to the mu and delta opioid receptors (MOR and DOR), and many KOR ligands have at least moderate affinity to MOR and/or DOR. Animal models utilizing primarily very long-lasting selective KOR antagonists (>3 weeks following a single dose) have demonstrated that KOR antagonism attenuates certain anxiety-like and depression-like behaviors and blocks stress- and cue-induced reinstatement to drug seeking. Recently, relatively selective KOR antagonists with medication-like pharmacokinetic and pharmacodynamic properties and durations of action have been developed. One of these, JNJ-67953964 (also referred to as CERC-501, LY2456302, OpraKappa or Aticaprant) has been studied in humans, and shown to be safe, relatively KOR selective, and able to substantially attenuate binding of a KOR PET tracer to CNS localized KOR for greater than 24 h. While animal studies have indicated that compounds of this structural class are capable of normalizing withdrawal signs in animal models of cocaine and alcohol dependence and reducing cocaine and alcohol intake/seeking, additional studies are needed to determine the value of these second generation KOR antagonists in treating mood disorders and substance use disorders in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- 5′AMN:
-
5′(2-aminomethyl) naltrindole
- 5′GNTI:
-
5′-guanidinonaltrindole
- 5′MABN:
-
N-((Naltrindol-5-yl)methyl)pentanimidamide
- ANTI:
-
5′acetamidinoethylnaltrindole
- AZ-MTAB:
-
3-((1R,3r,5S)-8-((5-MethylThiophen-2-yl)Methyl)-8- Azabicyclo [3.2.1]octan-3-yloxy)Benzamide
- DOR:
-
Delta opioid receptor
- i.p.:
-
Intraperitoneal
- KOR:
-
Kappa opioid receptor
- MOR:
-
Mu opioid receptor
- norBNI:
-
Norbinaltorphimine
- ROS:
-
Reactive oxygen species
- TENA:
-
(Triethylenedioxynaltrexamine)2
- THC:
-
Δ-9-tetrahydrocannabinol
References
Aldrich JV, Patkar KA, McLaughlin JP (2009) Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci U S A 106(43):18396–18401. https://doi.org/10.1073/pnas.0910180106
Aldrich JV, Senadheera SN, Ross NC, Ganno ML, Eans SO, McLaughlin JP (2013) The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J Nat Prod 76(3):433–438. https://doi.org/10.1021/np300697k
Bals-Kubik R, Herz A, Shippenberg TS (1989) Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology 98(2):203–206. https://doi.org/10.1007/bf00444692
Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005) Nalmefene induced elevation in serum prolactin in Normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30(12):2254–2262. https://doi.org/10.1038/sj.npp.1300811
Beardsley PM, Howard JL, Shelton KL, Carroll FI (2005) Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 183(1):118–126. https://doi.org/10.1007/s00213-005-0167-4
Bodnar RJ, Glass MJ, Ragnauth A, Cooper ML (1995) General, μ and κ opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Res 700(1):205–212. https://doi.org/10.1016/0006-8993(95)00957-R
Bruchas MR, Yang T, Schreiber S, DeFino M, Kwan SC, Li S, Chavkin C (2007) Long-acting κ opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating C-Jun N-terminal kinase. J Biol Chem 282(41):29803–29811. https://doi.org/10.1074/jbc.M705540200
Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Hoerter TN, Koether GM, Throner SR, Panko LM, Folmer JJ, Cacciola J, Hunter AM, Liu R, Edwards PD, Brown DG, Gordon J, Ledonne NC, Pietras M, Schroeder P, Sygowski LA, Hirata LT, Zacco A, Peters MF (2010) Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett 20(19):5847–5852. https://doi.org/10.1016/j.bmcl.2010.07.113
Buda JJ, Carroll FI, Kosten TR, Swearingen D, Walters BB (2015) A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral doses of JDTic. Neuropsychopharmacology 40(9):2059–2065. https://doi.org/10.1038/npp.2015.27
Butelman ER, Negus SS, Ai Y, de Costa BR, Woods JH (1993) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267(3):1269–1276
Butelman ER, Yuferov V, Kreek MJ (2012) κ-Opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35(10):587–596. https://doi.org/10.1016/j.tins.2012.05.005
Butelman ER, McElroy BD, Prisinzano TE, Kreek MJ (2019) Impact of pharmacological manipulation of the κ-opioid receptor system on self-grooming and Anhedonic-like behaviors in male mice. J Pharmacol Exp Ther 370(1):1–8. https://doi.org/10.1124/jpet.119.256354
Butelman ER, Fry RS, Kimani R, Reed B, Kreek MJ (2020) Neuroendocrine effects of naltrexone versus nalmefene in humans. Hum Psychopharmacol 35(2):e2726. https://doi.org/10.1002/hup.2726
Calcagnetti DJ, Calcagnetti RL, Fanselow MS (1990) Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine and MR2266, suppress intake of a sweet solution. Pharmacol Biochem Behav 35(1):69–73. https://doi.org/10.1016/0091-3057(90)90206-W
Carlezon WA Jr, Krystal AD (2016) Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety 33(10):895–906. https://doi.org/10.1002/da.22500
Carroll FI, Carlezon WA (2013) Development of κ opioid receptor antagonists. J Med Chem 56(6):2178–2195. https://doi.org/10.1021/jm301783x
Casal-Dominguez JJ, Clark M, Traynor JR, Husbands SM, Bailey SJ (2012) In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor. J Psychopharmacol 27(2):192–202. https://doi.org/10.1177/0269881112464828
Chang C, Byon W, Lu Y, Jacobsen LK, Badura LL, Sawant-Basak A, Miller E, Liu J, Grimwood S, Wang EQ, Maurer TS (2011) Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J 13(4):565–575. https://doi.org/10.1208/s12248-011-9296-3
Cheng H-YM, Laviolette SR, van der Kooy D, Penninger JM (2004) DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine. Eur J Neurosci 19(11):3033–3041. https://doi.org/10.1111/j.0953-816X.2004.03435.x
Cole JL, Berman N, Bodnar RJ (1997) Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats. Peptides 18(8):1201–1207. https://doi.org/10.1016/S0196-9781(97)00074-0
Domi E, Barbier E, Augier E, Augier G, Gehlert D, Barchiesi R, Thorsell A, Holm L, Heilig M (2018) Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders. Neuropsychopharmacology 43(9):1805–1812. https://doi.org/10.1038/s41386-018-0015-y
Dunn AD, Reed B, Erazo J, Ben-Ezra A, Kreek MJ (2019) Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem Neurosci 10(8):3590–3600. https://doi.org/10.1021/acschemneuro.9b00195
Eans SO, Ganno ML, Reilley KJ, Patkar KA, Senadheera SN, Aldrich JV, McLaughlin JP (2013) The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration. Br J Pharmacol 169(2):426–436. https://doi.org/10.1111/bph.12132
Ellingson HM, Vanderah TW (2020) Potential therapeutic treatments of cancer-induced bone pain. Curr Opin Support Palliat Care 14(2):107–111. https://doi.org/10.1097/spc.0000000000000496
Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharm Ther 316:30–42
Erickson S, Heul AV, Kim BS (2020) New and emerging treatments for inflammatory itch. Ann Allergy Asthma Immunol. https://doi.org/10.1016/j.anai.2020.05.028
Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22(3):1146–1154. https://doi.org/10.1523/jneurosci.22-03-01146.2002
Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR (2011) Pharmacological characterization of 2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors. J Pharmacol Exp Ther 339(2):555–566. https://doi.org/10.1124/jpet.111.185108
Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (2019) Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). J Med Chem 62(4):1761–1780. https://doi.org/10.1021/acs.jmedchem.8b01679
Horan P, Taylor J, Yamamura HI, Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260(3):1237–1243
Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY (2016a) Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol 781:53–59. https://doi.org/10.1016/j.ejphar.2016.03.061
Huang P, Yakovleva T, Aldrich JV, Tunis J, Parry C, Liu-Chen L-Y (2016b) Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests. Neurosci Lett 615:15–20. https://doi.org/10.1016/j.neulet.2016.01.017
Jacobson ML, Browne CA, Lucki I (2020) Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annu Rev Pharmacol Toxicol 60:615–636. https://doi.org/10.1146/annurev-pharmtox-010919-023317
Jarman SK, Haney AM, Valdez GR (2018) Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol. PLoS One 13(9):e0205016. https://doi.org/10.1371/journal.pone.0205016
Jewett DC, Woods JH (1995) Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons. Behav Pharmacol 6(8):815–820
Jones JD, Babalonis S, Marcus R, Vince B, Kelsh D, Lofwall MR, Fraser H, Paterson B, Martinez S, Martinez DM, Nunes EV, Walsh SL, Comer SD (2020) A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior. Addict Biol 25(4):e12799. https://doi.org/10.1111/adb.12799
Joynes RL, Grau JW (2004) Instrumental learning within the spinal cord: III. Prior exposure to noncontingent shock induces a behavioral deficit that is blocked by an opioid antagonist. Neurobiol Learn Mem 82(1):35–51. https://doi.org/10.1016/j.nlm.2004.04.001
Khaimova E, Kandov Y, Israel Y, Cataldo G, Hadjimarkou MM, Bodnar RJ (2004) Opioid receptor subtype antagonists differentially alter GABA agonist-induced feeding elicited from either the nucleus accumbens shell or ventral tegmental area regions in rats. Brain Res 1026(2):284–294. https://doi.org/10.1016/j.brainres.2004.08.032
Kishioka S, Kiguchi N, Kobayashi Y, Yamamoto C, Saika F, Wakida N, Ko MC, Woods JH (2013) Pharmacokinetic evidence for the long-lasting effect of nor-binaltorphimine, a potent kappa opioid receptor antagonist, in mice. Neurosci Lett 552:98–102. https://doi.org/10.1016/j.neulet.2013.07.040
Ko MC, Willmont KJ, Lee H, Flory GS, Woods JH (2003) Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res 982(1):38–44. https://doi.org/10.1016/s0006-8993(03)02938-x
Kormos CM, Ondachi PW, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Carroll FI (2017) Simple Tetrahydroisoquinolines are potent and selective kappa opioid receptor antagonists. ACS Med Chem Lett 8(7):742–745. https://doi.org/10.1021/acsmedchemlett.7b00115
Kotz CM, Grace MK, Billington CJ, Levine AS (1993) The effect of norbinaltorphimine, β-funaltrexamine and naltrindole on NPY-induced feeding. Brain Res 631(2):325–328. https://doi.org/10.1016/0006-8993(93)91552-4
Kreek MJ, LaForge KS, Butelman E (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1(9):710–726. https://doi.org/10.1038/nrd897
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ (2020) A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med 26(5):760–768. https://doi.org/10.1038/s41591-020-0806-7
Lalanne L, Ayranci G, Filliol D, Gavériaux-Ruff C, Befort K, Kieffer BL, Lutz PE (2017) Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence. Addict Biol 22(4):1010–1021. https://doi.org/10.1111/adb.12392
Laman-Maharg A, Williams AV, Zufelt MD, Minie VA, Ramos-Maciel S, Hao R, Sanchez EO, Copeland T, Silverman JL, Leigh A, Snyder R, Ivy Carroll F, Fennell TR, Trainor BC (2018) Sex differences in the effects of a Kappa opioid receptor antagonist in the forced swim test. Front Pharmacol 9. https://doi.org/10.3389/fphar.2018.00093
Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS (2000) Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. J Med Chem 43(8):1573–1576. https://doi.org/10.1021/jm000059g
Leventhal L, Kirkham TC, Cole JL, Bodnar RJ (1995) Selective actions of central μ and κ opioid antagonists upon sucrose intake in sham-fed rats. Brain Res 685(1):205–210. https://doi.org/10.1016/0006-8993(95)00385-4
Levine AS, Grace M, Billington CJ, Portoghese PS (1990) Nor-binaltorphimine decreases deprivation and opioid-induced feeding. Brain Res 534(1–2):60–64. https://doi.org/10.1016/0006-8993(90)90112-o
Levine AS, Grace M, Portoghese PS, Billington CJ (1994) The effect of selective opioid antagonists on butorphanol-induced feeding. Brain Res 637(1–2):242–248. https://doi.org/10.1016/0006-8993(94)91239-4
Li W, Sun H, Chen H, Yang X, Xiao L, Liu R, Shao L, Qiu Z (2016) Major depressive disorder and kappa opioid receptor antagonists. Trans Perioper Pain Med 1(2):4–16
Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn L, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S (2014) Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol 54(9):968–978. https://doi.org/10.1002/jcph.286
Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305(1):323–330. https://doi.org/10.1124/jpet.102.046433
Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35(4):283–323
Martínez V, Abalo R (2020) Peripherally acting opioid analgesics and peripherally-induced analgesia. Behav Pharmacol 31(2&3):136–158. https://doi.org/10.1097/fbp.0000000000000558
Melief EJ, Miyatake M, Carroll FI, Béguin C, Carlezon WA Jr, Cohen BM, Grimwood S, Mitch CH, Rorick-Kehn L, Chavkin C (2011) Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol 80(5):920–929. https://doi.org/10.1124/mol.111.074195
Metcalf MD, Coop A (2005) Kappa opioid antagonists: past successes and future prospects. AAPS J 7(3):E704–E722. https://doi.org/10.1208/aapsj070371
Munro TA, Berry LM, Van't Veer A, Béguin C, Carroll FI, Zhao Z, Carlezon WA Jr, Cohen BM (2012) Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol 12:5. https://doi.org/10.1186/1471-2210-12-5
Naganawa M, Jacobsen LK, Zheng M-Q, Lin S-F, Banerjee A, Byon W, Weinzimmer D, Tomasi G, Nabulsi N, Grimwood S, Badura LL, Carson RE, McCarthy TJ, Huang Y (2014) Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. NeuroImage 99:69–79. https://doi.org/10.1016/j.neuroimage.2014.05.033
Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE (2016) Receptor occupancy of the κ-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050. J Pharmacol Exp Ther 356(2):260–266. https://doi.org/10.1124/jpet.115.229278
Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T (2005) Direct evidence for the involvement of the mesolimbic κ-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 30(1):111–118. https://doi.org/10.1038/sj.npp.1300527
Ondachi PW, Kormos CM, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Fennell TR, Snyder RW, Carroll FI (2018) Potent and selective Tetrahydroisoquinoline kappa opioid receptor antagonists of Lead compound (3R)-7-Hydroxy-N-[(1S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic). J Med Chem 61(17):7525–7545. https://doi.org/10.1021/acs.jmedchem.8b00673
Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH (2019) Behavioral pharmacology of novel kappa opioid receptor antagonists in rats. Int J Neuropsychopharmacol 22(11):735–745. https://doi.org/10.1093/ijnp/pyz054
Patkar KA, Yan X, Murray TF, Aldrich JV (2005) [Nα-benzylTyr1,cyclo(D-Asp5,Dap 8)]-dynorphin A-(1-11)NH2 cyclized in the “address” domain is a novel κ-opioid receptor antagonist. J Med Chem 48(14):4500–4503. https://doi.org/10.1021/jm050105i
Patkar KA, Wu J, Ganno ML, Singh HD, Ross NC, Rasakham K, Toll L, McLaughlin JP (2013) Physical presence of nor-Binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on <em>κ</em>-opioid receptors. J Pharmacol Exp Ther 346(3):545–554. https://doi.org/10.1124/jpet.113.206086
Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, Brugel TA (2011) Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 661(1–3):27–34. https://doi.org/10.1016/j.ejphar.2011.04.017
Picker MJ, Mathewson C, Allen RM (1996) Opioids and rate of positively reinforced behavior: III. Antagonism by the long-lasting kappa antagonist norbinaltorphimine. Behav Pharmacol 7(6):495–504
Pizzagalli DA, Smoski M, Ang Y-S, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD (2020) Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the fast-fail trial in mood and anxiety Spectrum disorders (FAST-MAS). Neuropsychopharmacology 45:1656. https://doi.org/10.1038/s41386-020-0738-4
Portoghese PS, Takemori AE (1985) TENA, a selective kappa opioid receptor antagonist. Life Sci 36(8):801–805. https://doi.org/10.1016/0024-3205(85)90202-4
Portoghese PS, Lipkowski AW, Takemori AE (1987) Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40(13):1287–1292. https://doi.org/10.1016/0024-3205(87)90585-6
Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE (1988a) Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem 31(4):836–841. https://doi.org/10.1021/jm00399a026
Portoghese PS, Nagase H, Takemori AE (1988b) Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. J Med Chem 31(7):1344–1347. https://doi.org/10.1021/jm00402a015
Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin CE, Takemori AE (1991) Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine. J Med Chem 34(4):1292–1296. https://doi.org/10.1021/jm00108a008
Reed B, Fang N, Mayer-Blackwell B, Chen S, Yuferov V, Zhou Y, Kreek MJ (2012) Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. Neuroscience 220:109–118. https://doi.org/10.1016/j.neuroscience.2012.06.006
Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ (2018) Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacology 43(4):739–750. https://doi.org/10.1038/npp.2017.205
Rorick-Kehn LM, Witcher JW, Lowe SL, Gonzales CR, Weller MA, Bell RL, Hart JC, Need AB, McKinzie JH, Statnick MA, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Stoltz RR, Wong CJ (2014a) Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human. Int J Neuropsychopharmacol 18(2). https://doi.org/10.1093/ijnp/pyu036
Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL (2014b) LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 77:131–144. https://doi.org/10.1016/j.neuropharm.2013.09.021
Ross NC, Reilley KJ, Murray TF, Aldrich JV, McLaughlin JP (2012) Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism. Br J Pharmacol 165(4b):1097–1108. https://doi.org/10.1111/j.1476-5381.2011.01544.x
Saito T, Hirai H, Kim YJ, Kojima Y, Matsunaga Y, Nishida H, Sakakibara T, Suga O, Sujaku T, Kojima N (2002) CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502. J Antibiot (Tokyo) 55(10):847–854. https://doi.org/10.7164/antibiotics.55.847
Schattauer SS, Land BB, Reichard KL, Abraham AD, Burgeno LM, Kuhar JR, Phillips PEM, Ong SE, Chavkin C (2017) Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase. Nat Commun 8(1):743. https://doi.org/10.1038/s41467-017-00791-2
Schattauer SS, Bedini A, Summers F, Reilly-Treat A, Andrews MM, Land BB, Chavkin C (2019) Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation. J Biol Chem 294(45):16884–16896. https://doi.org/10.1074/jbc.RA119.009592
Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A, Kreek MJ (1998) Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res 22(7):1430–1436. https://doi.org/10.1111/j.1530-0277.1998.tb03931.x
Spanagel R, Shippenberg TS (1993) Modulation of morphine-induced sensitization by endogenous κ opioid systems in the rat. Neurosci Lett 153(2):232–236. https://doi.org/10.1016/0304-3940(93)90329-J
Stahl EL, Zhou L, Ehlert FJ, Bohn LM (2015) A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Mol Pharmacol 87(5):866–877. https://doi.org/10.1124/mol.114.096503
Stevens WC Jr, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS (2000) Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem 43(14):2759–2769. https://doi.org/10.1021/jm0000665
Takemori AE, Ho BY, Naeseth JS, Portoghese PS (1988) Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246(1):255–258
Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, Cantrell BE, Zimmerman DM, Carroll FI (2001) Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J Med Chem 44(17):2687–2690. https://doi.org/10.1021/jm015521r
Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA (2004) Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172(4):463–470. https://doi.org/10.1007/s00213-003-1680-y
Urbano M, Guerrero M, Rosen H, Roberts E (2014) Antagonists of the kappa opioid receptor. Bioorg Med Chem Lett 24(9):2021–2032. https://doi.org/10.1016/j.bmcl.2014.03.040
Valenza M, Butelman ER, Kreek MJ (2017) Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats. Psychopharmacology 234(15):2219–2231. https://doi.org/10.1007/s00213-017-4647-0
Valenza M, Windisch KA, Butelman ER, Reed B, Kreek MJ (2020) Effects of kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat. Psychopharmacology 237(4):1147–1160. https://doi.org/10.1007/s00213-019-05444-4
Varlinskaya EI, Johnson JM, Przybysz KR, Deak T, Diaz MR (2020) Adolescent forced swim stress increases social anxiety-like behaviors and alters kappa opioid receptor function in the basolateral amygdala of male rats. Prog Neuro-Psychopharmacol Biol Psychiatry 98:109812. https://doi.org/10.1016/j.pnpbp.2019.109812
Ved HS, Doshi GM (2020) A review on emerging drug targets in treatment of schizophrenia. Curr Drug Targets 21. https://doi.org/10.2174/1389450121666200615150429
Verhoest PR, Sawant Basak A, Parikh V, Hayward M, Kauffman GW, Paradis V, McHardy SF, McLean S, Grimwood S, Schmidt AW, Vanase-Frawley M, Freeman J, Van Deusen J, Cox L, Wong D, Liras S (2011) Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem 54(16):5868–5877. https://doi.org/10.1021/jm2006035
Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Morris ED, Carson RE, Huang Y (2013) Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med 54(3):455–463. https://doi.org/10.2967/jnumed.112.109512
Zimmer A, Valjent E, Konig M, Zimmer AM, Robledo P, Hahn H, Valverde O, Maldonado R (2001) Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 21(23):9499–9505. https://doi.org/10.1523/jneurosci.21-23-09499.2001
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Reed, B., Butelman, E.R., Kreek, M.J. (2020). Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. In: Liu-Chen, LY., Inan, S. (eds) The Kappa Opioid Receptor. Handbook of Experimental Pharmacology, vol 271. Springer, Cham. https://doi.org/10.1007/164_2020_401
Download citation
DOI: https://doi.org/10.1007/164_2020_401
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-89073-5
Online ISBN: 978-3-030-89074-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)